Philochem AG Announces up to $1.35 Billion License Agreement With RayzeBio

Reston – June 10, 2025 – Cooley advised Philochem AG, a wholly owned subsidiary of the Philogen Group (Milan Stock Exchange: PHIL), on its definitive license agreement with RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), granting RayzeBio exclusive worldwide rights to develop, manufacture and commercialize OncoACP3, a clinical-stage therapeutic and diagnostic agent targeting prostate cancer. Under the terms of the agreement, Philochem will receive a $350 million up-front payment and up to $1 billion in development, regulatory and commercial milestones. Philochem will also receive mid-single- to low-double-digit royalties on global net sales of OncoACP3 therapeutic and diagnostic agents.

Lawyers Ken Krisko, Joe Sandys, Alexandra Paterson, Joseph Perry and Brian Stalter led the global cross-office Cooley team advising Philochem, with invaluable support from Megan Browdie, David Burns, Aaron Pomeroy, Amanda Pacheco, Natasha Leskovsek, Rachel Thorn and Ann Bevitt.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.